Deciphering The Tumor Genome: Exploring Molecular and Clinical Advances in the DNA Damage Response Pathway

Activity Details
  • Credit Amounts:
    • CME: 1.00
    • CNE: 1.00
    • Other: 1.00
    • P.A.C.E.: 1.00
    • NSGC: 1.00
  • Cost: Free
  • Release: Jul 17, 2018
  • Expires: Jul 17, 2019
  • Estimated Time to Complete:
    1 Hour(s)
  • System Requirements:
  • Average User Rating:
    (5 Ratings)

Faculty

Justine Pickarski Justine Pickarski, MS, LGC
Certified Genetic Counselor
University of Kentucky
Markey Cancer Center
Lexington, KY

Nadine M.  Tung Nadine M. Tung, MD
Chief, Breast Oncology
Director, Cancer Genetics and Prevention Program
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Needs Statement

Our understanding of underlying genetic mechanisms that drive tumorigenesis has exponentially increased over the last several years. As a result, there has been an ever-growing shift in the treatment paradigm for various cancer types, many of which have focused on personalized therapies that exploit vulnerabilities in tumor DNA. Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated efficacy in BRCA-mutated tumors (i.e., ovarian, breast, prostate, and pancreatic), as well as in those with other genes defective in the DNA damage repair pathway. While the introduction of such targeted therapies has dramatically expanded treatment options for cancer patients, it also has introduced complexities to clinical decision making and care, including the selection of patients for genetic testing, appropriate timing of testing, and interpretation of genetic information. As the use of precision therapy and accompanying diagnostics are increasingly incorporated into the future of cancer care, clinicians involved in genetic testing and counseling will become increasingly essential to the oncology team and will play a major role in the care of cancer patients.

Participants will gain understanding of the genes involved in DNA damage response (DDR) pathways and their role in tumorigenesis; the latest advances to clinically target the DDR, including the use of PARP inhibitors; and the most recent updates in genetic testing and counseling guidelines. Using a case-based approach, this educational initiative will address challenging, relevant questions that may include discussion on genetic testing strategies, result interpretation, therapy selection, and counseling topics for cancer patients and their families.

Target Audience

Genetic counselors, medical and clinical geneticists, laboratory researchers, nurses, physicians, physician assistants, and all medical practitioners who are involved in the diagnosis, management, and genetic counseling of patients who have or are at risk for DDR-mutated cancers.

Objectives

Upon completion of this activity, participants will be able to:

1. Outline the role of the DNA damage response (DDR) pathway in tumor suppression and describe how mutations in DDR genes lead to tumor proliferation.

2. Explore recent advances in the discovery of actionable mutations in DDR (e.g., BRCA1/2) and the developments in precision medicine targeting these mutations, including poly (ADP-ribose) polymerase (PARP) inhibitors.

3. Assess current guideline recommendations for genetic testing and counseling in patients with possible or known pathogenic DNA damage response mutations.

4. Using a case-based approach, evaluate challenging questions encountered in the genetic testing and counseling of BRCA1/2 and other DDR mutations, and discuss the evolving role of the genetic counselor in the interprofessional oncology care team.

Accreditation

NSGC

The National Society of Genetic Counselors (NSGC) has authorized Creative Educational Concepts to offer up to 0.1 CEUs or 1 Category 1 contact hours for the activity Deciphering The Tumor Genome: Exploring Molecular and Clinical Advances in the DNA Damage Response Pathway.The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.

CME

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CEC designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ACGME Competencies

  • Medical knowledge
  • Practice-based learning and improvement

IOM Competencies

  • Employ evidence-based practice

IPE Competencies

  • Interprofessional Communication

CNE

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is designated for 1.00 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

P.A.C.E.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Creative Educational Concepts is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ®

Program Provider Number: 416-001-18

Other

Creative Educational Concepts, Inc. certifies this activity for 1.00 hour of participation.

 

Faculty Disclosure

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/ partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner

Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters

Justine Cooper Pickarski, MS, CGC—has no relevant financial relationships to disclose in relation to the content of this activity.

Nadine Tung, MD—has no relevant financial relationships to disclose in relation to the content of this activity.

Peer Reviewers

Susan H. Scher, MD—has no relevant financial relationships to disclose in relation to the content of this activity.

Paula J. Anastasia, RN, MN, AOCN—has disclosed that she is a consultant for Clovis and Genentech.